The anticoagulant properties of mast cell product, chondroitin sulphate E.
The anticoagulant potency in vitro of chondroitin sulphate E has been found to be similar to that of the heparinoids. In purified systems chondroitin sulphate E was shown to be principally an activator of heparin cofactor II. Maximum acceleration of heparin cofactor II:thrombin interaction was 185-fold (9.3 X 10(7) M-1 min-1), antithrombin III:thrombin interaction was 11-fold (4.16 X 10(6) M-1 min-1) and antithrombin III:factor Xa was 146-fold (3.86 X 10(6) M-1 min-1). Chondroitin sulphate E was observed to prolong the thrombin clotting time of fibrinogen in the absence of antithrombin III and heparin cofactor II. The effect appeared to be related to interference in thrombin:fibrinogen interaction rather than in fibrin monomer polymerization.
D000925:Anticoagulants; D000990:Antithrombin III / Q000378:metabolism; D001777:Blood Coagulation / Q000187:drug effects*; D002807:Chondroitin / Q000031:analogs & derivatives*; D002809:Chondroitin Sulfates / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D005170:Factor X / Q000378:metabolism; D015951:Factor Xa; D005340:Fibrinogen / Q000378:metabolism; D006023:Glycoproteins / Q000378:metabolism; D006493:Heparin / Q000494:pharmacology; D015844:Heparin Cofactor II; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D008407:Mast Cells / Q000502:physiology*; D013917:Thrombin / Q000378:metabolism
D000925:Anticoagulants; D006023:Glycoproteins; D015844:Heparin Cofactor II; D000990:Antithrombin III; D005170:Factor X; D005340:Fibrinogen; D006493:Heparin; D002807:Chondroitin; D002809:Chondroitin Sulfates; D013917:Thrombin; D015951:Factor Xa